Why Twist Bioscience Stock Skyrocketed This Week

TWST shares jumped over 31% this week after the company announced a partnership with LLY to join Lilly TuneLab, an AI-driven drug discovery platform. TWST will provide antibody characterization data services through its AbLab model, generating revenue while gaining access to advanced research capabilities developed by the pharmaceutical giant.

The collaboration positions TWST as both a service provider and participant in LLY's AI-powered initiative, allowing the synthetic biology company to monetize its antibody expertise while contributing to and learning from the platform's evolving datasets. TWST's AbLab model will support characterization workflows within the Lilly TuneLab ecosystem.

The 31% weekly gain reflects investor optimism that the partnership opens a recurring revenue stream tied to one of the world's largest pharmaceutical companies while strengthening TWST's position in the AI-enabled biologics discovery market.